Tarsons Products Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The regulatory filing was made on April 09, 2026, to both BSE Limited and National Stock Exchange of India Limited.

Regulatory Compliance Certificate

The certificate was issued by KFin Technologies Limited, serving as the Registrar and Share Transfer Agent for Tarsons Products Limited. The document confirms that all required details regarding securities dematerialized and rematerialized during the quarter have been properly furnished to the stock exchanges where the company's shares are listed.

Stock Exchange Notification

The compliance certificate was formally submitted to both major Indian stock exchanges where Tarsons Products shares are traded. The company maintains its listing on BSE with scrip code 543399 and on NSE under the symbol TARSONS.

Depositories Confirmation

KFin Technologies Limited, as the appointed Registrar and Share Transfer Agent, issued separate certificates to both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). These certificates, dated April 01, 2026, were signed by Bhaskar Roy, Deputy Vice President at KFin Technologies Limited.

Corporate Governance

The filing demonstrates Tarsons Products Limited's commitment to maintaining regulatory compliance and transparent corporate governance practices. Santosh Kumar Agarwal, who serves as CFO, Company Secretary and Compliance Officer with ICSI Membership No. A44836, signed the submission on behalf of the company.

This quarterly certification process ensures that all securities transactions involving dematerialization and rematerialization are properly documented and reported to relevant regulatory authorities, maintaining the integrity of the securities market infrastructure.

Tarsons products Limited has completed an equity investment of EUR 300,000 in its wholly-owned subsidiary Tarsons Life Science Pte. Ltd., Singapore, as disclosed to stock exchanges under Regulation 30 on April 09, 2026. This investment represents a significant step in the company's international expansion strategy and subsidiary funding initiatives.

Investment Details

The equity investment involved the subscription of 100 equity shares at a nominal value of EUR 3,000 per share, totaling EUR 300,000. This investment is part of a larger planned equity infusion of EUR 3,000,000 that was initially announced to stock exchanges on February 06, 2026.

Purpose and Utilization

The invested funds will serve multiple strategic purposes for the Singapore subsidiary. The primary utilization includes quarterly repayment of loans taken from banks in Singapore, along with interest payments on these loans. Additionally, the funds will support general corporate purposes and cover various operational and financial expenses of the subsidiary.

Subsidiary Profile

Tarsons Life Science Pte. Ltd. was incorporated in Singapore on November 10, 2023, and operates as a Special Purpose Vehicle in the non-operating financial holding companies sector. The subsidiary maintains its status as a wholly-owned subsidiary of Tarsons Products Limited, with no change in ownership percentage following this investment.

Regulatory Compliance

The transaction falls within the ambit of related party transactions and has been conducted on an arm's length basis. Key directors including Mr. Aryan Sehgal, Mr. Sanjive Sehgal, and Mr. Subramanian Arun Kumar hold directorships in both the parent company and the subsidiary. The company has confirmed that no governmental or regulatory approvals were required for this acquisition.

Future Investment Plans

Tarsons Products Limited has indicated that it will continue to inform stock exchanges as and when further tranches of equity investments are made in the subsidiary. This suggests that the current EUR 300,000 investment is the first installment of the larger EUR 3,000,000 equity infusion plan announced earlier.

The completion of this investment demonstrates the company's commitment to strengthening its international presence and ensuring adequate capitalization of its overseas operations. The structured approach to funding through multiple tranches allows for better cash flow management while meeting the subsidiary's operational requirements.